Περίληψη:
Animal and experimental data suggest that anti-Mullerian hormone (AMH)
serves as a marker of ovarian reserve and inhibits the growth of ovarian
tumors. However, few epidemiologic studies have examined the association
between AMH and ovarian cancer risk. We conducted a nested case-control
study of 302 ovarian cancer cases and 336 matched controls from nine
cohorts. Prediagnostic blood samples of premenopausal women were assayed
for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated using
multivariable-adjusted conditional logistic regression. AMH
concentration was not associated with overall ovarian cancer risk. The
multivariable-adjusted OR (95% CI), comparing the highest to the lowest
quartile of AMH, was 0.99 (0.59-1.67) (P-trend: 0.91). The association
did not differ by age at blood draw or oral contraceptive use (all
P-heterogeneity: >= 0.26). There also was no evidence for heterogeneity
of risk for tumors defined by histologic developmental pathway, stage,
and grade, and by age at diagnosis and time between blood draw and
diagnosis (all P-heterogeneity: >= 0.39). In conclusion, this analysis
of mostly late premenopausal women from nine cohorts does not support
the hypothesized inverse association between prediagnostic circulating
levels of AMH and risk of ovarian cancer.
Συγγραφείς:
Jung, Seungyoun
Allen, Naomi
Arslan, Alan A.
Baglietto,
Laura
Barricarte, Aurelio
Brinton, Louise A.
Egleston, Brian
L.
Falk, Roni T.
Fortner, Renee T.
Helzlsouer, Kathy J. and
Gao, Yutang
Idahl, Annika
Kaaks, Rudolph
Krogh, Vittorio and
Merritt, Melissa A.
Lundin, Eva
Onland-Moret, N. Charlotte and
Rinaldi, Sabina
Schock, Helena
Shu, Xiao-Ou
Sluss, Patrick
M.
Staats, Paul N.
Sacerdote, Carlotta
Travis, Ruth C. and
Tjonneland, Anne
Trichopoulou, Antonia
Tworoger, Shelley S. and
Visvanathan, Kala
Weiderpass, Elisabete
Zeleniuch-Jacquotte,
Anne
Dorgan, Joanne F.
